Cormorant Asset Management
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles.
Business Model:
Revenue: $27.4M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Cormorant Asset Management Information
Geographic Data
Address:
City: Chagrin Falls
State: OH
Zip: 44022
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$253M
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace. Cormorant Asset Management was founded in 2013 and is based in Boston, Massachusetts, United States.
Contact Phone:
+14402473200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 2/2021 | Ensoma | Series A | 0 |
| 1/2016 | Twist Bioscience | Series D | 61M |
| 8/2020 | Aerovate Therapeutics | Series A | 72.6M |
| 11/2017 | X4 Pharmaceuticals | Series B | 27M |
| 2/2018 | Kiniksa Pharmaceuticals | Series C | 200M |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 10/2017 | InflaRx | Series D | 55M |
| 5/2020 | Atea | Series D | 215M |
| 4/2021 | GH Research | Series B | 125M |
| 9/2020 | Galecto | Series D | 0 |
| 7/2015 | AnaptysBio | Series D | 40M |
| 10/2020 | Longboard Pharmaceuticals | Series A | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 2/2019 | NuVera Medical | Series B | 15M |
| 3/2020 | Element Science | Series C | 145.6M |
| 9/2018 | PhaseBio Pharmaceuticals | Series D | 0 |
| 2/2019 | Neurogene | Series A | 68.5M |
| 9/2021 | Garuda Therapeutics | Series A | 72M |
| 6/2020 | Greenlight Biosciences | Series D | 102M |
| 8/2022 | JenaValve Technology | Series C | 0 |
| 1/2023 | Ensoma | Series B | 0 |
| 6/2018 | Iconic Therapeutics | Venture Round | 0 |
| 8/2021 | Tango Therapeutics | Post-IPO Equity | 0 |
| 1/2016 | Scholar Rock | Series B | 36M |
| 1/2016 | Iconic Therapeutics | Series C | 40M |
| 8/2016 | Iconic Therapeutics | Series C | 10M |
| 5/2023 | OnKure Therapeutics | Series C | 0 |
| 5/2016 | G1 Therapeutics | Series C | 0 |
| 9/2020 | Monte Rosa Therapeutics | Series B | 0 |
| 4/2021 | Icosavax | Series B | 0 |
| 1/2022 | Korro Bio | Series B | 0 |
| 3/2017 | Solid Biosciences | Series C | 0 |
| 7/2020 | Praxis Precision Medicines | Series C | 0 |
| 8/2022 | Greenlight Biosciences | Post-IPO Equity | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 2/2021 | Artiva Biotherapeutics | Series B | 120M |
| 12/2020 | RayzeBio | Series B | 105M |
| 3/2021 | Monte Rosa Therapeutics | Series C | 0 |
| 3/2020 | Akouos | Series B | 105M |
| 6/2021 | Stablix | Series A | 63M |
| 8/2017 | Apellis Pharmaceuticals | Series E | 0 |
| 4/2022 | Tessera Therapeutics | Series C | 0 |
| 3/2017 | 908 Devices | Series D | 20M |
| 8/2015 | Wave Life Sciences | Series B | 66M |
| 9/2020 | Fore Biotherapeutics | Series C | 57M |
| 6/2017 | Zai Lab | Series C | 30M |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 3/2021 | AgomAb Therapeutics | Series B | 0 |
| 9/2020 | BioShin | Series A | 60M |
| 5/2021 | Jenscare Biotech | Venture Round | - |
| 7/2020 | BioAtla | Series D | 0 |
| 3/2021 | Tyra Biosciences | Series B | 106M |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 10/2018 | Turning Point Therapeutics | Equity | 80M |
| 3/2021 | DTx Pharma | Series B | 100M |
| 4/2020 | Tango Therapeutics | Series B | 60M |
| 4/2018 | Innovent Biologics | Series E | 150M |
| 4/2017 | NuVera Medical | Series A | 11M |
| 10/2021 | Structure Therapeutics | Series B | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2022 | FogPharma | Series D | 0 |
| 11/2021 | Shoreline Biosciences | Series B | 0 |
| 1/2021 | Design Therapeutics | Series B | 125M |
| 6/2016 | Mersana Therapeutics | Series C | 33M |
| 6/2023 | Myra Vision | Series B | 0 |
| 1/2021 | Beam Therapeutics | Post-IPO Equity | 260M |
| 9/2020 | Eledon Pharmaceuticals | Post-IPO Equity | 108M |
| 4/2015 | MyoKardia | Series B | 0 |
| 2/2015 | Advaxis | Post-IPO Equity | 0 |
| 1/2022 | ONK Therapeutics | Series A | 21.5M |
| 2/2021 | Centessa Pharmaceuticals | Series A | 250M |
| 12/2015 | Gelesis | Private Equity Round | 0 |
| 7/2020 | VelosBio | Series B | 137M |
| 3/2021 | OnKure | Series B | 56.6M |
| 8/2018 | Orchard Therapeutics | Series C | 0 |
| 5/2021 | Numab | Series C | 110.6M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 9/2017 | Autolus | Series C | 80M |
| 1/2022 | Akura Medical | Series A | 25M |
| 8/2015 | Ovid Therapeutics | Series B | 75M |
| 12/2021 | connectRN | Venture Round | 0 |
| 7/2021 | Prime Medicine | Series B | 200M |
| 10/2020 | Talaris Therapeutics | Series B | 0 |
| 4/2018 | Corvidia | Series B | 60M |
| 2/2022 | Star Therapeutics | Venture Round | 0 |
| 3/2016 | ImmuneXcite | Series A | 8.6M |
| 8/2014 | MyoKardia | Venture Round | 0 |
| 7/2017 | Kezar Life Sciences | Series B | 0 |
| 3/2020 | Pliant Therapeutics | Series C | 0 |
| 12/2017 | Bigfoot Biomedical | Series B | 0 |
| 12/2015 | Axonics Modulation Technologies | Series B | 0 |
| 5/2021 | Elpiscience Biopharmaceuticals | Series C | 0 |
| 2/2023 | Tioga Cardiovascular | Series C | 0 |
| 11/2022 | BioAtla | Post-IPO Equity | 0 |
| 4/2018 | Constellation Pharmaceuticals | Series F | 0 |
| 7/2021 | Strata Oncology | Series C | 0 |
| 6/2015 | CytomX Therapeutics | Series D | 70M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 1/2020 | Bigfoot Biomedical | Series C | 0 |
| 11/2019 | Avidity Biosciences | Series C | 0 |
| 6/2021 | Myra Vision | Series A | 17M |
| 2/2022 | Arkuda Therapeutics | Series B | 0 |
| 7/2020 | New Horizon Health | Series E | 30M |
| 8/2022 | Atia Vision | Series E | 0 |
| 5/2015 | REGENXBIO | Series D | 0 |
| 1/2016 | C4 Therapeutics | Series A | 73M |
| 9/2020 | Flame Biosciences | Venture Round | 100M |
| 8/2018 | Renovia | Series B | 32.3M |
| 9/2015 | Proteostasis Therapeutics | Series B | 37M |
| 3/2020 | Supira Medical | Series B | 0 |
| 7/2017 | Axonics Modulation Technologies | Series C | 20.5M |
| 3/2021 | Neurelis | Series D | 0 |
| 5/2021 | Interius BioTherapeutics | Series A | 0 |
| 10/2020 | Olema Oncology | Series C | 85M |
| 9/2021 | Expansion Therapeutics | Series B | 80M |
| 3/2019 | Beam Therapeutics | Series B | 135M |
| 4/2018 | Eidos Therapeutics | Series B | 0 |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 2/2022 | Electra Therapeutics | Series B | 0 |
| 2/2022 | Supira Medical | Series C | 0 |
| 3/2016 | Quanterix | Series D | 46M |
| 12/2019 | FORMA Therapeutics | Series D | 100M |
| 12/2015 | Clearside Biomedical | Series C | 20M |
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 5/2019 | Atia Vision | Series D | 0 |
| 3/2015 | Minerva Neuroscience | Post-IPO Equity | 0 |
| 10/2016 | Bigfoot Biomedical | Series A | 0 |
| 4/2015 | Jounce Therapeutics | Series B | 0 |
| 9/2021 | BioAtla | Post-IPO Equity | 0 |
| 4/2023 | BioVentrix | Series A | 0 |
| 2/2022 | Greenlight Biosciences | Post-IPO Equity | 0 |
| 1/2021 | Visen Pharmaceuticals | Series B | 0 |
| 9/2020 | Korro Bio | Series A | 0 |
| 4/2022 | MoonLake Immunotherapeutics | Post-IPO Equity | 115M |
| 5/2021 | BiVACOR | Series B | 19M |
| 1/2021 | FogPharma | Series C | 107M |
| 5/2017 | Axonics Modulation Technologies | Series C | 0 |
| 9/2015 | Aclaris Therapeutics | Series C | 40M |
| 9/2021 | 858 Therapeutics | Series A | 0 |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 6/2015 | Ardelyx | Post-IPO Equity | 77.8M |
| 9/2017 | Replimune Group | Series B | 55M |
| 3/2021 | EpimAb Biotherapeutics | Series C | 0 |
| 8/2017 | Atreca | Series B | 35M |
| 4/2020 | Erasca | Series B | 0 |
| 1/2018 | Scholar Rock | Series C | 47M |
| 9/2018 | Atreca | Series C | 125M |
| 6/2021 | Myra Vision | Series A | 17M |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 11/2020 | Pharvaris | Series C | 80M |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 3/2021 | Chemomab | Post-IPO Equity | 45.5M |
| 1/2021 | Verve Therapeutics | Series B | 94M |
| 7/2020 | Olema Oncology | Series B | 54M |
| 8/2021 | Vigil Neuroscience | Series B | 0 |
| 5/2017 | Turning Point Therapeutics | Series C | 45M |
| 9/2020 | I-Mab Biopharma | Post-IPO Equity | 0 |
| 2/2016 | Apellis Pharmaceuticals | Series D | 47M |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 12/2020 | Edgewise Therapeutics | Series C | 95M |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 11/2020 | Elevation Oncology | Series B | 65M |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 9/2020 | Novellus | Series C | 57M |
| 10/2022 | Orionis Biosciences | Series C | 55M |
| 8/2020 | Freenome | Series C | 270M |
| 7/2021 | Tioga Medical | Series B | 0 |
| 2/2020 | ALX Oncology | Series C | 105M |
| 6/2021 | Umoja Biopharma | Series B | 0 |
| 3/2018 | Bigfoot Biomedical | Series B | 0 |
| 9/2020 | Rain Therapeutics | Series B | 63M |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 1/2021 | Biomea Fusion | Series A | 56M |
| 1/2022 | Enliven Therapeutics | Series B | 0 |
| 12/2015 | X4 Pharmaceuticals | Series A | 37.5M |
| 11/2017 | Tricida | Series D | 0 |
| 3/2021 | BlossomHill Therapeutics | Series A | 71M |
| 12/2018 | Atia Vision | Series C | 10M |
| 3/2017 | Dicerna Pharmaceuticals | Post-IPO Debt | 0 |
| 6/2018 | Cibus | Series C | 70M |
| 2/2018 | Avrobio | Series B | 60M |
| 4/2018 | Supira Medical | Series A | 15.5M |
| 11/2021 | Chroma Medicine | Series A | 125M |
| 11/2020 | Ambrx | Private Equity Round | 200M |
| 6/2015 | Kezar Life Sciences | Series A | 23M |
| 12/2018 | Erasca | Series A | 42M |
| 3/2020 | Design Therapeutics | Series A | 45.5M |
| 10/2021 | ShouTi | Series B | 0 |
| 9/2020 | Adona Medical | Series A | 0 |
| 4/2022 | Adona Medical | Series B | 0 |
| 6/2019 | Viela Bio | Series B | 0 |
| 8/2020 | Tango Therapeutics | Venture Round | 50M |
| 6/2023 | Myra Vision | Series B | 0 |
| 5/2023 | OnKure Therapeutics | Series C | 0 |
| 4/2023 | BioVentrix | Series A | 0 |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 2/2023 | Tioga Cardiovascular | Series C | 0 |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 1/2023 | Ensoma | Series B | 0 |
| 11/2022 | FogPharma | Series D | 0 |
| 11/2022 | BioAtla | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
